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Acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) are cancers of the type of white 
blood cells known as myeloid cells. Both AML and the advanced stage of CML, blast crisis (BC), are 
characterized by the overgrowth of abnormal immature hematopoietic cells that accumulate in the 
bone marrow and interfere with normal blood cell development. One subtype of AML, acute 
promyelocytic leukemia (APL), can be treated with drugs that drive the differentiation of leukemic 
cells to mature myeloid cells that eventually die. However, other subtypes of AML are resistant to the 
effects of these drugs. Understanding why other subtypes of AML have a block in cell differentiation 
may lead to novel therapeutic strategies. A new study led by postdoctoral fellow Dr. Valerie Morris in 
the laboratory of Dr. Vivian Oehler (Clinical Research Division) describes a role for microRNA-150 in 
controlling differentiation and cell growth in myeloid leukemias. 
MicroRNAs (miRNAs) are short non-protein coding RNAs that control protein levels in cells. These 
miRNAs have many biological roles, including regulation of normal blood cell development, and their 
levels are altered in leukemias. Morris et al. determined that miRNA-150 levels were significantly 
lower in both BC CML and AML patient cells than in healthy bone marrow cells, and a subset of 
adult AML patient samples had 100 to 1000-fold lower miRNA-150 levels. The decrease in miRNA-
150 levels was observed across multiple molecular subtypes of AML. In pediatric AML patient 
samples, miR-150 expression was lowest in patients stratified to have poor-risk status by molecular 
changes. 
To determine if decreased miRNA-150 expression plays a functional role in leukemia cells, the 
researchers overexpressed miRNA-150 in four human AML cell lines with low levels of miRNA-150 
expression. During myeloid differentiation, cells undergo a characteristic change in their morphology 
and acquire the expression of specific cell surface markers.  In all cell lines examined by the 
researchers, miRNA-150 decreased cell growth and increased myeloid differentiation as determined 
by morphology under the microscope and cell surface marker expression by flow cytometry (see 
figure). This effect was augmented with drugs, such as all-trans retinoic acid (ATRA), which 
differentiate these cell lines.  Furthermore, cells overexpressing miRNA-150 demonstrated increased 
expression of genes associated with myeloid differentiation by gene expression analysis. 
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Morris et al. then examined the effect of miRNA-150 on normal human hematopoietic progenitor 
cells.  Again, the researchers observed that miRNA-150 expression promoted myeloid differentiation 
as evidenced by changes in morphology, cell surface markers, and gene expression, as well as the 
ability to form myeloid colonies in methylcellulose. Notably, the authors saw similar effects by 
reintroducing miRNA-150 expression in six different human AML patient cells and two BC CML 
patient samples. 
Previous published work had defined a role for miRNA-150 in development of other blood cells, 
specifically T and B cells, natural killer cells, and megakaryocytes. miRNA-150 exerts its effects in 
these cells by targeting the transcription factor MYB. MYB is expressed in progenitor cells to 
maintain self-renewal of cells and MYB expression is decreased in fully mature myeloid cells. In the 
AML cell lines, miRNA-150 decreased MYB protein expression. Overexpression of MYB could 
partially abrogate the effect of miRNA-150 on myeloid differentiation, suggesting that miRNA-150 
functioned, at least in part, by decreasing MYB protein levels. 
These results support a previously uncharacterized role for miRNA-150 in promoting myeloid 
differentiation, and demonstrate that low miRNA-150 expression contributes to the leukemic 
phenotype in various AML subtypes and BC CML. Confirming these results, a published study using 
a murine model of AML showed that miRNA-150 expression decreased the proliferation of leukemic 
cells and increased the survival of mice (Jiang et al., 2012). "The discovery of non-coding RNAs has 
dramatically altered our thinking regarding how normal cells and cancer cells are regulated and 
identified a completely novel way that cancer cells may be targeted in the future. We are now using 
high-throughput miRNA library screening approaches to identify other miRNAs with currently 
unknown roles in cell differentiation, growth or death and examining how a subset of these miRNAs 
are regulated," according to Dr. Oehler.  "Lastly, although, still technically difficult, one ultimate goal 
is to establish if miRNAs can be therapeutics in their own right and if so which are the best 
candidates." 
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Image provided by Dr. Valerie Morris 
Expression of miRNA-150 promotes differentiation of human 
AML cells as determined by cell surface markers of 
differentiation (CD11b) and morphology compared to control 
cells. HL-60 cells were assayed in the absence and presence of 
differentiation agent all-trans retinoic acid (ATRA). 
 
